FI3694863T3 - Lorlatinibin vapaan emäksen hydraatin kidemuoto - Google Patents
Lorlatinibin vapaan emäksen hydraatin kidemuoto Download PDFInfo
- Publication number
- FI3694863T3 FI3694863T3 FIEP18795807.9T FI18795807T FI3694863T3 FI 3694863 T3 FI3694863 T3 FI 3694863T3 FI 18795807 T FI18795807 T FI 18795807T FI 3694863 T3 FI3694863 T3 FI 3694863T3
- Authority
- FI
- Finland
- Prior art keywords
- ppm
- crystal form
- free base
- base hydrate
- cancer
- Prior art date
Links
- 239000012458 free base Substances 0.000 title claims 7
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 title claims 7
- 229950001290 lorlatinib Drugs 0.000 title claims 7
- 239000013078 crystal Substances 0.000 claims 12
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims 2
- 238000001144 powder X-ray diffraction data Methods 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000806 fluorine-19 nuclear magnetic resonance spectrum Methods 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570326P | 2017-10-10 | 2017-10-10 | |
| US201862727734P | 2018-09-06 | 2018-09-06 | |
| PCT/IB2018/057735 WO2019073347A1 (en) | 2017-10-10 | 2018-10-04 | CRYSTALLINE BASE FREE HYDRATE SHAPE OF LORLATINIB |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3694863T3 true FI3694863T3 (fi) | 2023-08-18 |
Family
ID=64049474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18795807.9T FI3694863T3 (fi) | 2017-10-10 | 2018-10-04 | Lorlatinibin vapaan emäksen hydraatin kidemuoto |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11299500B2 (enExample) |
| EP (1) | EP3694863B1 (enExample) |
| JP (1) | JP7153069B2 (enExample) |
| KR (1) | KR102424621B1 (enExample) |
| CN (1) | CN111201235B (enExample) |
| AU (1) | AU2018349259B2 (enExample) |
| CA (1) | CA3077508C (enExample) |
| CY (1) | CY1126141T1 (enExample) |
| DK (1) | DK3694863T3 (enExample) |
| ES (1) | ES2952985T3 (enExample) |
| FI (1) | FI3694863T3 (enExample) |
| HU (1) | HUE062926T2 (enExample) |
| MX (1) | MX2020003373A (enExample) |
| PL (1) | PL3694863T3 (enExample) |
| PT (1) | PT3694863T (enExample) |
| RU (1) | RU2022109286A (enExample) |
| SG (1) | SG11202002445SA (enExample) |
| SI (1) | SI3694863T1 (enExample) |
| TW (1) | TWI775960B (enExample) |
| WO (1) | WO2019073347A1 (enExample) |
| ZA (1) | ZA202001661B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2842302T3 (es) | 2015-07-31 | 2021-07-13 | Pfizer | Forma cristalina de base libre de lorlatinib |
| EP3440086B1 (en) | 2016-04-08 | 2020-08-12 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| US20210163498A1 (en) * | 2018-04-23 | 2021-06-03 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| WO2021011345A1 (en) * | 2019-07-18 | 2021-01-21 | Pliva Hrvatska D.O.O | Crystalline lorlatinib : fumaric acid and solid state form thereof |
| CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
| EP4041396A1 (en) | 2019-10-10 | 2022-08-17 | Sandoz AG | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| WO2021176349A1 (en) | 2020-03-05 | 2021-09-10 | Pfizer Inc. | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
| CN111362967B (zh) * | 2020-04-28 | 2021-09-07 | 南京雷正医药科技有限公司 | 苯并氧杂二氮杂十四碳烯衍生物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013525476A (ja) | 2010-05-04 | 2013-06-20 | ファイザー・インク | Ａｌｋ阻害剤としての複素環式誘導体 |
| EP2643314B1 (en) * | 2010-11-25 | 2016-07-13 | ratiopharm GmbH | Novel salts and polymorphic forms of afatinib |
| US9422226B2 (en) | 2011-06-08 | 2016-08-23 | Biogen Ma Inc. | Process for preparing high purity and crystalline dimethyl fumarate |
| HUE034118T2 (en) | 2012-03-06 | 2018-01-29 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| EP3013835B1 (en) * | 2013-06-28 | 2017-12-13 | Pfizer Inc | Solid forms of a macrocyclic kinase inhibitor |
| EP3183256A4 (en) * | 2014-08-20 | 2018-05-30 | Teligene Ltd. | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| WO2016026423A1 (en) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| ES2842302T3 (es) | 2015-07-31 | 2021-07-13 | Pfizer | Forma cristalina de base libre de lorlatinib |
| EP3440086B1 (en) | 2016-04-08 | 2020-08-12 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
-
2018
- 2018-10-04 JP JP2020520115A patent/JP7153069B2/ja active Active
- 2018-10-04 DK DK18795807.9T patent/DK3694863T3/da active
- 2018-10-04 AU AU2018349259A patent/AU2018349259B2/en active Active
- 2018-10-04 SG SG11202002445SA patent/SG11202002445SA/en unknown
- 2018-10-04 US US16/650,505 patent/US11299500B2/en active Active
- 2018-10-04 CN CN201880065709.6A patent/CN111201235B/zh active Active
- 2018-10-04 PL PL18795807.9T patent/PL3694863T3/pl unknown
- 2018-10-04 FI FIEP18795807.9T patent/FI3694863T3/fi active
- 2018-10-04 RU RU2022109286A patent/RU2022109286A/ru unknown
- 2018-10-04 CA CA3077508A patent/CA3077508C/en active Active
- 2018-10-04 PT PT187958079T patent/PT3694863T/pt unknown
- 2018-10-04 KR KR1020207010512A patent/KR102424621B1/ko active Active
- 2018-10-04 ES ES18795807T patent/ES2952985T3/es active Active
- 2018-10-04 MX MX2020003373A patent/MX2020003373A/es unknown
- 2018-10-04 EP EP18795807.9A patent/EP3694863B1/en active Active
- 2018-10-04 SI SI201830952T patent/SI3694863T1/sl unknown
- 2018-10-04 HU HUE18795807A patent/HUE062926T2/hu unknown
- 2018-10-04 WO PCT/IB2018/057735 patent/WO2019073347A1/en not_active Ceased
- 2018-10-05 TW TW107135186A patent/TWI775960B/zh active
-
2020
- 2020-03-17 ZA ZA2020/01661A patent/ZA202001661B/en unknown
-
2023
- 2023-07-25 CY CY20231100357T patent/CY1126141T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019073347A1 (en) | 2019-04-18 |
| MX2020003373A (es) | 2020-10-12 |
| PT3694863T (pt) | 2023-08-23 |
| TWI775960B (zh) | 2022-09-01 |
| CA3077508C (en) | 2023-02-14 |
| US11299500B2 (en) | 2022-04-12 |
| KR20200051781A (ko) | 2020-05-13 |
| HUE062926T2 (hu) | 2023-12-28 |
| CA3077508A1 (en) | 2019-04-18 |
| EP3694863A1 (en) | 2020-08-19 |
| CY1126141T1 (el) | 2023-11-15 |
| EP3694863B1 (en) | 2023-06-21 |
| US20200308191A1 (en) | 2020-10-01 |
| ZA202001661B (en) | 2023-11-29 |
| AU2018349259A1 (en) | 2020-04-09 |
| BR112020005989A2 (pt) | 2020-09-29 |
| PL3694863T3 (pl) | 2023-09-25 |
| JP2020536893A (ja) | 2020-12-17 |
| TW201922753A (zh) | 2019-06-16 |
| RU2020113141A (ru) | 2021-11-12 |
| SG11202002445SA (en) | 2020-04-29 |
| SI3694863T1 (sl) | 2023-10-30 |
| JP7153069B2 (ja) | 2022-10-13 |
| CN111201235B (zh) | 2023-02-10 |
| ES2952985T3 (es) | 2023-11-07 |
| DK3694863T3 (da) | 2023-07-03 |
| RU2022109286A (ru) | 2022-05-06 |
| CN111201235A (zh) | 2020-05-26 |
| AU2018349259B2 (en) | 2021-02-18 |
| RU2020113141A3 (enExample) | 2021-11-12 |
| KR102424621B1 (ko) | 2022-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3694863T3 (fi) | Lorlatinibin vapaan emäksen hydraatin kidemuoto | |
| RU2018101363A (ru) | Кристаллическая форма свободного основания лорлатиниба | |
| FI2134702T4 (fi) | 6-[2-(metyylikarbamoyyli)fenyylisulfanyyli]-3-E-[2-(pyridiini-2-yyli)etenyyli]indatsolin kidemuotoja jotka soveltuvat nisäkkäiden poikkeavan solukasvun hoitamiseen | |
| JP2020536893A5 (enExample) | ||
| MY169142A (en) | Macrocyclic derivatives for the treatment of proliferative diseases | |
| JP2014162794A5 (enExample) | ||
| PH12016500911A1 (en) | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders | |
| IL276948A (en) | N- (Cyanomethyl) -4– (2– (4-morpholinophenylamino) pyrimidine-4-il) salts Benzamide hydrochloride | |
| JP2017039702A5 (enExample) | ||
| TN2019000133A1 (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| WO2014209841A3 (en) | Compounds for treating spinal muscular atrophy | |
| WO2018102452A3 (en) | Using substituted pyrazole compounds for treatment of hyperproliferative diseases | |
| FI4214202T3 (fi) | Cdk4-estäjän kiinteät muodot | |
| JP2016528242A5 (enExample) | ||
| JP2020511467A5 (enExample) | ||
| JP2015509536A5 (enExample) | ||
| MX2015010858A (es) | Formas solidas de un inhbidor de cdk4/6 selectivo. | |
| TW200635924A (en) | Chemical compounds | |
| PH12013501727A1 (en) | Heteroaryl derivatives as alpha7 nachr modulators | |
| MX373612B (es) | Cristal del compuesto alquinil benceno 3,5-disustituido. | |
| MX2009009574A (es) | Tratamiento de melanoma. | |
| JP2015522037A5 (enExample) | ||
| NZ734152A (en) | Compounds, compositions and methods useful for cholesterol mobilisation | |
| MX381000B (es) | Cristales de compuesto azabicíclico. | |
| RU2012146517A (ru) | Соли ральтегравира и их кристаллические формы |